Liangsu Wang has over 25 years of healthcare experience in all stages of drug discovery in multiple therapeutic areas. Her previous professional experiences include VP of External Innovation at Johnson & Johnson; VP – Head of Biology at Morphic Therapeutics; and Executive Director – Cardiometabolic Disease Research at Merck. She was a key contributor to the successful series B financing and IPO for Morphic in 2019, leading to a $3.2 billion acquisition by Eli Lilly in 2024.

Liangsu holds a Ph.D. from University of Calgary and a B.S. from Fudan University.